These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

922 related items for PubMed ID: 26465779

  • 1. Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers.
    Killinger BA, Moszczynska A.
    J Neurochem; 2016 Feb; 136(3):510-25. PubMed ID: 26465779
    [Abstract] [Full Text] [Related]

  • 2. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
    McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE.
    Neuropharmacology; 2015 Jun; 93():146-54. PubMed ID: 25645392
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity.
    Liu B, Traini R, Killinger B, Schneider B, Moszczynska A.
    Exp Neurol; 2013 Sep; 247():359-72. PubMed ID: 23313192
    [Abstract] [Full Text] [Related]

  • 4. Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.
    Miller DB, O'Callaghan JP, Ali SF.
    Ann N Y Acad Sci; 2000 Sep; 914():194-207. PubMed ID: 11085321
    [Abstract] [Full Text] [Related]

  • 5. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.
    Granado N, Ares-Santos S, O'Shea E, Vicario-Abejón C, Colado MI, Moratalla R.
    Neurotox Res; 2010 Jul; 18(1):48-58. PubMed ID: 19760475
    [Abstract] [Full Text] [Related]

  • 6. Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen.
    Pereira FC, Lourenço ES, Borges F, Morgadinho T, Ribeiro CF, Macedo TR, Ali SF.
    Synapse; 2006 Sep 01; 60(3):185-93. PubMed ID: 16739116
    [Abstract] [Full Text] [Related]

  • 7. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure.
    Harvey DC, Laćan G, Melegan WP.
    Exp Brain Res; 2000 Aug 01; 133(3):349-58. PubMed ID: 10958525
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats.
    Xi ZX, Kleitz HK, Deng X, Ladenheim B, Peng XQ, Li X, Gardner EL, Stein EA, Cadet JL.
    Neuroscience; 2009 Jun 30; 161(2):392-402. PubMed ID: 19336247
    [Abstract] [Full Text] [Related]

  • 10. Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity.
    Lu T, Kim PP, Greig NH, Luo Y.
    Neurotox Res; 2017 Aug 30; 32(2):218-230. PubMed ID: 28342134
    [Abstract] [Full Text] [Related]

  • 11. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
    McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.
    J Pharmacol Exp Ther; 2012 Feb 30; 340(2):295-303. PubMed ID: 22034657
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain.
    Yu J, Cadet JL, Angulo JA.
    J Neurochem; 2002 Nov 30; 83(3):613-22. PubMed ID: 12390523
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
    Sriram K, Miller DB, O'Callaghan JP.
    J Neurochem; 2006 Feb 30; 96(3):706-18. PubMed ID: 16405514
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation.
    McConnell SE, O'Banion MK, Cory-Slechta DA, Olschowka JA, Opanashuk LA.
    Neurotoxicology; 2015 Sep 30; 50():131-41. PubMed ID: 26283213
    [Abstract] [Full Text] [Related]

  • 18. 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.
    Anneken JH, Angoa-Pérez M, Kuhn DM.
    J Neurochem; 2015 Apr 30; 133(2):211-22. PubMed ID: 25626880
    [Abstract] [Full Text] [Related]

  • 19. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA.
    Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R.
    Neurobiol Dis; 2011 Jun 30; 42(3):391-403. PubMed ID: 21303698
    [Abstract] [Full Text] [Related]

  • 20. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2001 May 30; 169(1):83-95. PubMed ID: 11312561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.